Clinical trial

Envafolimab Plus Docetaxel In Combination With or Without Trilaciclib Versus Docetaxel in Advanced NSCLC

NCT05910034

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2023-07-01

PhasePHASE2

Study timeline

Study start (estimated)2023-07-01Date precision: day

Registry last updated2023-06-18

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Advanced Non-Small Cell Lung Cancerunresolved

Interventions

Trilaciclib+Envafolimab+DocetaxelDRUG

Envafolimab+DocetaxelDRUG

DocetaxelDRUG · verified · RxNorm: docetaxel

Sponsors & collaborators

Fudan Universitylead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05910034 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.